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Abstract: Background: The effect of synchronous chemotherapy in squamous cell carcinoma of
the head and neck (SCCHN) has been modelled as additional Biologically Effective Dose (BED) or
as a prolonged tumour cell turnover time during accelerated repopulation. Such models may not
accurately predict the local control seen when hypofractionated accelerated radiotherapy is used with
synchronous chemotherapy. Methods: For the purposes of this study three isoeffect relationships
were assumed: Firstly, from the RTOG 0129 trial, synchronous cisplatin chemotherapy with 70 Gy in
35 fractions over 46 days results in equivalent local control to synchronous cisplatin chemotherapy
with 36 Gy in 18# followed by 36 Gy in 24# (2# per day) over a total of 39 days. Secondly, in line with
primary local control outcomes from the PET-Neck study, synchronous cisplatin chemotherapy with
70 Gy in 35# over 46 days results in equivalent local control to synchronous cisplatin chemotherapy
delivered with 65 Gy in 30# over 39 days. Thirdly, from meta-analysis data, 70 Gy in 35# over
46 days with synchronous cisplatin results in equivalent local control to 84 Gy in 70# over 46 days
delivered without synchronous chemotherapy. Using the linear quadratic equation the above isoeffect
relationships were expressed algebraically to determine values of α, α/β, and k for SCCHN when
treated with synchronous cisplatin using standard parameters for the radiotherapy alone schedule
(α = 0.3 Gy−1, α/β = 10 Gy, and k = 0.42 Gy10day−1). Results: The values derived for α/β, α and k
were 2 Gy, 0.20 and 0.21 Gy−1, and 0.65 and 0.71 Gy2day−1. Conclusions: Within the limitations of
the assumptions made, this model suggests that accelerated repopulation may remain a significant
factor when synchronous chemotherapy is delivered with radiotherapy in SCCHN. The finding of a
low α/β for SCCHN treated with cisplatin suggests a greater tumour susceptibility to increasing dose
per fraction and underlines the importance of the completion of randomized trials examining the role
of hypofractionated acceleration in SCCHN.
Keywords: head and neck cancer; chemoradiation; linear quadratic equation
1. Introduction
Twenty Eight years have passed since the linear quadratic (LQ) equation was proposed as a
model for use in comparing radiotherapy fractionation schedules and 10 years since the late Professor
Jack Fowler published his overviews of the optimal timing for radiotherapy alone schedules in
squamous cell carcinoma of the head and head and neck cancer (SCCHN) [1–4]. Over this time, the LQ
equation has been employed to predict potential benefits from proposed new fractionation schedules.
However, the LQ equation with standard modification for repopulation fails to model the lack of
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benefit gained from accelerated fractionation with synchronous chemotherapy when this is compared
with synchronous chemotherapy delivered with standard fractionation in SCCHN [5,6].
Five years ago a suppression of accelerated repopulation by synchronous chemotherapy as an
explanation for the lack of benefit from accelerated fractionation in this setting was proposed [7]. This
adjusted model gives reasonable predictions for many historic trials.
A recent meta-analysis has shown that roughly equivalent improvements in survival can be
achieved either with synchronous chemotherapy and standard fractionation (70 Gy in 35# delivered
over 46 days) or with hyperfractionated dose escalated radiotherapy alone (e.g., 84 Gy in 70# delivered
over 46 days) [8]. These two schedules are yet to be directly compared in a randomized study.
If the biologically effective dose for tumour (tBED) is calculated for both schedules using Equation (1)
(α = 0.3 Gy−1; β = 0.03 Gy−2; Tk = 21 days; Tp = 3 days for radiotherapy alone or 10 days with
synchronous chemotherapy) BEDs of 78 Gy10 and 75 Gy10, respectively, are obtained [3].
tBED = D
[
1 +
(
d
α
β
)]
−
[
ln2
α
× (T − Tk)
Tp
]
(1)
where tBED = biologically effective dose for tumour (Gyα/β), D = total dose (Gy), d = dose per fraction
(Gy), α = linear component of cell kill (Gy−1), β = quadratic component cell kill (Gy−2) T = overall
treatment time (days), Tk = kick off time (days) (modelled time of commencement of accelerated
repopulation), and Tp = clonogen doubling time (days).
If the log cell kill is calculated using Equation (2) log cell kills of 10.2 and 9.7 are obtained.
log10 cell kill =
tBED ∗ α(
log10
loge
) (2)
where tBED = biologically effective dose for tumour (Gyα/β) and α = linear component of cell kill (Gy−1).
If the dose gradient or ratio of % change in local control to % change in tBED at this dose level is
assumed from previous modelling to be 1.2, a difference in local control of approximately 5% might be
expected [9]. Such a difference would require a very large randomized study to detect. In addition,
in certain head and neck sub groups the dose gradient may be significantly less than 1.2 within this
dose range, thus any difference between these approaches would be even more difficult to detect.
In the United Kingdom (UK), there is a commonly held assumption that the standard fractionation
70 Gy/35# over 46 days is equivalent to 65 Gy/30# over 39 days when both are administered
with synchronous chemotherapy [10,11]. This assumption is evidenced by the use of the six week
hypofractionated accelerated schedule with synchronous chemotherapy as the standard arm in
randomized studies [12,13]. Using Equations (1) and (2) (Tp = 10 days as both arms employ
synchronous chemotherapy), the BEDs and log cell kills of 70 Gy/35# over 46 days and 65 Gy/30#
over 39 days are 78 Gy10 and 75 Gy10 and 10.2 and 9.8. Assuming a dose gradient of 1.2, the modelling
would predict a 5% difference in local control. Data from the PET-Neck study appear to show
equivalent control rates between the two fractionation schedules when synchronous chemotherapy
was delivered [14].
One of the limitations of the modification to the LQ model, where the effect of accelerated
repopulation is assumed to be reduced by synchronous chemotherapy, is that the potential
effect of synchronous chemotherapy on fraction size sensitivity is ignored. While a significantly
less steep dose response gradient in certain head and neck sub-types e.g., Human Papilloma
Virus (HPV) related HNSCC may partially explain the apparent equivalence of the UK six week
hypofractionated accelerated regime to the standard, the purpose of this paper was to explore simple
mathematical solutions where chemotherapy is modelled to effect both fraction size sensitivity and
accelerated repopulation.
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2. Methods
Three assumptions about clinical efficacy of chemoradiation schedules in a hypothetical SCCHN
population were made. The first two assumptions use regime comparisons where both fraction size
and overall treatment time varied between the comparators.
Firstly, in line with the results of the Radiotherapy and Oncology Group (RTOG) 0129 trial cisplatin
chemotherapy delivered with 70 Gy in 35 fractions over 46 days (schedule 1) results in equivalent
local control to the same chemotherapy delivered with 36 Gy delivered in 18 fractions followed by
36 Gy delivered in 24 fractions (2 fractions per day) over a total of 39 days (schedule 2) [5]. Secondly
in line with the assumption made by UK clinical oncologists discussed in the introduction, cisplatin
chemotherapy delivered with 70 Gy in 35 fractions over 46 days results in equivalent local control to
the same chemotherapy delivered with 65 Gy in 30 fractions over 39 days (schedule 3).
To express this mathematically the dose loss to accelerated repopulation component of Equation (1)
was simplified to give Equation (3).
tBED = D
[
1 +
(
d
α
β
)]
− kT (3)
where tBED = biologically effective dose for tumour (Gyα/β), D = total dose (Gy), d = dose per fraction
(Gy), α = linear component of cell kill (Gy−1), β = quadratic component cell kill (Gy−2), T = overall
treatment time (days), k = dose loss per day (Gyα/βday−1) where accelerated population is assumed to
occur equally over the overall treatment time, i.e.:
kT =
[
ln2
α
× (T − Tk)
Tp
]
(4)
This implies a value of k for a standard 7 week course of radiotherapy delivered without
synchronous chemotherapy (70 Gy in 35 fractions over 46 days) (α = 0.3 Gy−1; Tk = 21; Tp = 3
days) of 0.42 Gy10day−1
The first clinical assumption was then expressed as:
tBEDschedule 1 = tBEDschedule 2 (5)
Substituting values for the two schedules gives:
70
[
1 +
(
2
α
β
)]
− k46 = 36
[
1 +
(
2
α
β
)]
+ 36
[
1 +
(
1.5
α
β
)]
− k39 (6)
This can be simplified to:
α
β
=
14
7k+ 2
. (7)
The second clinical assumption was then expressed as:
tBEDschedule 1 = tBEDschedule 3 (8)
Substituting values for the two schedules gives:
70
[
1 +
(
2
α
β
)]
− k46 = 65
[
1 +
(
2.17
α
β
)]
− k39 (9)
which can be simplified to:
α
β
=
1.05
5− 7k (10)
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The curves for Equations (5) and (7) were then plotted to determine possible values for α/β and k.
In order to calculate the value of α for potential values of α/β and k, the third assumption, namely
that the log10cell kill of 70 Gy in 35 fractions with synchronous cisplatin is approximately equivalent to
the log10cell kill of 84 Gy in 70 fractions radiation alone (calculated in the introduction to be 9.7) was
used based on meta-analysis data [8].
Based on the potential values of α/β and k extracted from the graph in Figure 1, the tBED for
70 Gy in 35 fractions with synchronous chemotherapy was first calculated using Equation (3). α was
then calculated by re-arranging Equation (2) using this tBED.
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3. Results
The curves for Equations (5) and (7) are represented in Figure 1. The curves cross at a value of α/β
2 Gy with value of k 0.65 Gy2day−1 or 0.71 Gy2day−1.
For α/β = 2 y and k = 0.65 Gy2day−1, α = 0.20 Gy−1. For α/β = 2 Gy and k = 0.71 Gy2day−1,
α = 0.21 Gy−1.
The log cell kill of various che oradiation fractionation schedules is docu ented in Table 1 for
the above values.
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Table 1. Comparison of log cell kill values predicted for various regimes administered with synchronous chemotherapy using parameters derived in this paper.
Regime Reference Total Dose (Gy) Fractions Dose Per Fraction(Gy)
Overall
Treatment Time
(Days)
Log10Cell Kill
(α/β = 2 Gy; k = 0.65 Gy2day−1;
α = 0.20 Gy−1)
Log10Cell Kill
(α/β = 2 Gy; k = 0.71 Gy2day−1;
α = 0.21 Gy−1)
International Standard [15] 70 35 2.00 46 9.7 9.7
UK Alternative 6 weeks [12–14] 65 30 2.17 39 9.7 9.7
Manchester/Birmingham
4 weeks [16–19] 55 20 2.75 25 10.1 10.2
ART-DECO experimental
arm 5.5 weeks [12] 67.2 28 2.40 37 10.9 11.0
COMPARE experimental
arm 5 weeks [20] 64 25 2.56 32 11.0 11.1
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4. Discussion
The derivation of values of α/β of 2 Gy, k approximately 0.7 Gy2day−1, and α approximately
0.2 Gy−1 are based on three assumptions: the equivalence of the worldwide standard of 70 Gy in
35 fractions over 46 days with synchronous cisplatin to firstly the RTOG hyperfractionated regime
72 Gy in 42 fractions over 39 days, to secondly the UK hypofractionated regime 65 Gy in 30 fractions
over 39 days, and to thirdly the hyperfractionated dose escalated regime 84 Gy in 70 fractions over
46 days without synchronous chemotherapy. The first of these assumptions is based on the outcome
of a randomized trial, the third on a meta-analysis and the second is an assumption widely held
among UK clinicians participating in randomized trials but also supported by data from the PET-Neck
study [5,8,14].
In addition to the assumptions stated above, there are several limitations to such modelling.
Firstly, these values are based on equivalence in a hypothetical head and neck population. In reality,
they will vary for individual tumours and therefore the mean values of these parameters will likely
vary for example between populations of p16+ve oropharyngeal carcinoma, p16-ve oropharyngeal
carcinoma, early laryngeal carcinoma and locally advanced laryngeal/hypopharyngeal carcinoma.
In addition, the values for patients receiving neoadjuvant chemotherapy are likely to be different.
Despite these limitations, this paper attempts to propose modelling of synchronous cisplatin
chemotherapy in HNSCC by alteration of both fraction sensitivity and accelerated repopulation
parameters. Such modelling suggests that in the presence of synchronous chemotherapy accelerated
repopulation may remain a significant factor and in addition fraction sensitivity may be increased by
synchronous chemotherapy. We have not attempted, in this paper, to model the effect of synchronous
chemotherapy on parameters related to acute mucositis. For these reasons, continued examination of
synchronous chemotherapy with dose escalated hypofractionated accelerated regimes is warranted
in appropriate populations within prospective randomized trials. While the use of neoadjuvant
chemotherapy will affect the values of the parameters calculated in this paper by reducing clonogen
number, it may make any benefit from the increased log cell kill predicted with such regimes difficult
to detect in national randomized trials. Similarly, the inclusion of large numbers of patients with small
volume good prognosis tumours may also mask any benefit. These regimes should initially be tested
therefore in poor prognosis groups in the absence of neoadjuvant chemotherapy such as the ongoing
international COMPARE study [20,21].
5. Conclusions
The parameters calculated in this paper suggest a continued role for the investigation of
hypofractionated accelerated regimens with synchronous chemotherapy provided this is done in
an appropriately poor prognosis, locally advanced population with regimes which have been tested
prior to sufficiently large phase 3 trials. The assumptions and the limitations of this and all modelling
mean this is hypothesis generating only and requires rigorous prospective validation.
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